AT Bancorp reduced its stake in Shire PLC (NASDAQ:SHPG) by 32.3% during the third quarter, Holdings Channel reports. The firm owned 13,021 shares of the biopharmaceutical company’s stock after selling 6,207 shares during the period. AT Bancorp’s holdings in Shire PLC were worth $2,523,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Rail Splitter Capital Management LLC purchased a new stake in shares of Shire PLC during the second quarter valued at approximately $6,461,000. Cullen Frost Bankers Inc. bought a new position in Shire PLC during the second quarter worth about $17,387,000. Bienville Capital Management LLC bought a new position in Shire PLC during the second quarter worth about $450,000. CAM Group Holding A S increased its position in Shire PLC by 1.5% in the second quarter. CAM Group Holding A S now owns 106,494 shares of the biopharmaceutical company’s stock worth $19,603,000 after buying an additional 1,570 shares during the period. Finally, Westport Resources Management Inc. bought a new position in Shire PLC during the second quarter worth about $318,000. 22.78% of the stock is owned by hedge funds and other institutional investors.
Shire PLC (NASDAQ:SHPG) traded down 0.22% on Monday, hitting $174.84. 907,315 shares of the stock traded hands. Shire PLC has a 52-week low of $147.60 and a 52-week high of $215.05. The company’s 50 day moving average price is $179.87 and its 200-day moving average price is $187.59.
Shire PLC (NASDAQ:SHPG) last issued its earnings results on Tuesday, November 1st. The biopharmaceutical company reported $3.17 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.21 by $0.04. Shire PLC had a return on equity of 14.81% and a net margin of 1.62%. The company earned $3.45 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter in the prior year, the business posted $3.24 EPS. The company’s revenue for the quarter was up 108.6% compared to the same quarter last year. On average, equities analysts expect that Shire PLC will post $12.93 earnings per share for the current fiscal year.
A number of research firms have issued reports on SHPG. Leerink Swann set a $198.00 price target on Shire PLC and gave the company a “buy” rating in a research note on Monday, November 14th. Jefferies Group set a $248.00 price target on Shire PLC and gave the company a “buy” rating in a research note on Friday, November 11th. RBC Capital Markets reiterated an “outperform” rating and set a $235.00 price target on shares of Shire PLC in a research note on Friday, November 11th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Shire PLC in a research note on Monday, November 7th. Finally, Citigroup Inc. reiterated a “buy” rating on shares of Shire PLC in a research note on Thursday, November 3rd. Four investment analysts have rated the stock with a hold rating and twenty-three have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $222.06.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.